Gastric Ulcer Clinical Trial
Official title:
Comparison of Ulcer Healing in Patients Taking Rabeprazole Plus Aspirin Versus Rabeprazole Plus Clopidogrel for Acute Peptic Ulcer
Clopidogrel causes significantly less peptic ulcer disease (PUD) and ulcer bleeding than
low-dose aspirin in general population. However, clopidogrel is not safe enough for
gastrointestinal (GI) mucosa in patients who had past history of aspirin-associated ulcer or
ulcer bleeding. Aspirin plus proton pump inhibitor (PPI) is superior to clopidogrel alone in
preventing recurrent ulcer bleeding in these high risk patients.
This study is to compare the ulcer healing rate and ulcer bleeding at 12 weeks in patients
with aspirin-associated PUD when they take PPI (rabeprazole 20 mg/day) to treat their PUD
and simultaneously take aspirin or clopidogrel for their cardiovascular (CV) prevention. Two
hundred patients will be randomly assigned rabeprazole (20 mg/day) plus aspirin (100 mg/day)
or rabeprazole (20 mg/day) plus clopidogrel (75 mg/day) for 12 weeks. The primary end point
is treatment success (ulcer healing rate). The secondary end point is incidence of ulcer
bleeding within 12 weeks.
If rabeprazole plus aspirin in not inferior to rabeprazole plus clopidogrel in the incidence
of ulcer healing and ulcer bleeding in the healing phase,PPI plus aspirin rather than PPI
plus clopidogrel will be recommended during acute ulcer healing in patients who need
antiplatelet therapy for their CV prevention.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05518929 -
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
|
Phase 4 | |
| Completed |
NCT03291418 -
To Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05526339 -
HFNO Combined With NPA Reduces Hypoxia During Sedated Gastrointestinal Endoscopy In Obese Patients
|
N/A | |
| Completed |
NCT01435525 -
Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation
|
N/A | |
| Completed |
NCT00527787 -
Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen
|
Phase 3 | |
| Terminated |
NCT00594854 -
Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec
|
Phase 3 | |
| Completed |
NCT01129011 -
Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen
|
Phase 3 | |
| Recruiting |
NCT05517408 -
Dose Exploration of Ciprofol for Sedation in Gastrointestinal Endoscopic Diagnosis and Treatment of Obese Patients.
|
N/A | |
| Recruiting |
NCT01946633 -
Remote-controlled Capsule Endoscopy: a Feasibility Study
|
N/A | |
| Completed |
NCT01964131 -
BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects
|
Phase 1 | |
| Completed |
NCT01150162 -
Mucosta in Gastric Ulcer Treatment, Effectiveness and Safety Evaluation
|
Phase 3 | |
| Completed |
NCT00961350 -
A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers
|
Phase 3 | |
| Completed |
NCT00960869 -
Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers
|
Phase 3 | |
| Completed |
NCT00595517 -
Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer
|
Phase 3 | |
| Completed |
NCT00428701 -
An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium
|
Phase 4 | |
| Completed |
NCT01452711 -
Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric Ulcer
|
Phase 3 | |
| Terminated |
NCT05579444 -
Systems Biology of Gastrointestinal and Related Diseases
|
||
| Completed |
NCT02761512 -
Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer
|
Phase 3 | |
| Recruiting |
NCT03057171 -
A Study on the Gastrointestinal Disease and Helicobacter Pylori Controlled Long Non-coding RNA
|
||
| Completed |
NCT01568398 -
A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy
|
Phase 3 |